Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 209

1.

Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus.

Steinhart AH, Panaccione R, Targownik L, Bressler B, Khanna R, Marshall JK, Afif W, Bernstein CN, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C.

J Can Assoc Gastroenterol. 2018 Dec;1(4):141-154. doi: 10.1093/jcag/gwy047. Epub 2018 Sep 14. Review.

2.

Systematic review of nutrition screening and assessment in inflammatory bowel disease.

Li S, Ney M, Eslamparast T, Vandermeer B, Ismond KP, Kroeker K, Halloran B, Raman M, Tandon P.

World J Gastroenterol. 2019 Jul 28;25(28):3823-3837. doi: 10.3748/wjg.v25.i28.3823.

3.

Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.

Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN.

J Can Assoc Gastroenterol. 2019 Aug;2(3):e1-e34. doi: 10.1093/jcag/gwz019. Epub 2018 Jul 10.

4.

A Cholangioscopy-Based Novel Classification System for the Phenotypic Stratification of Dominant Bile Duct Strictures in Primary Sclerosing Cholangitis-the Edmonton Classification.

Sandha G, D'Souza P, Halloran B, Montano-Loza AJ.

J Can Assoc Gastroenterol. 2018 Dec;1(4):174-180. doi: 10.1093/jcag/gwy020. Epub 2018 May 11.

5.

Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study.

Shim HH, Ma C, Kotze PG, Seow CH, Al-Farhan H, Al-Darmaki AK, Pang JXQ, Fedorak RN, Devlin SM, Dieleman LA, Kaplan GG, Novak KL, Kroeker KI, Halloran BP, Panaccione R.

J Can Assoc Gastroenterol. 2018 Sep;1(3):115-123. doi: 10.1093/jcag/gwy013. Epub 2018 May 10.

6.

Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.

Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN.

Clin Gastroenterol Hepatol. 2019 Aug;17(9):1680-1713. doi: 10.1016/j.cgh.2019.02.043. Epub 2019 Mar 7.

PMID:
30853616
7.

CFTR dysfunction increases endoglin and TGF-β signaling in airway epithelia.

Nicola T, Kabir FL, Coric T, Wall SB, Zhang W, James M, MacEwen M, Ren C, Halloran B, Ambalavanan N, Harris WT.

Physiol Rep. 2019 Feb;7(4):e13977. doi: 10.14814/phy2.13977.

8.

Absorbent materials to collect urine can affect proteomics and metabolomic biomarker concentrations.

Boohaker L, Halloran B, Wilson L, Berryhill T, Barnes S, Griffin R, Askenazi D.

Clin Chem Lab Med. 2019 May 27;57(6):e134-e137. doi: 10.1515/cclm-2018-0931. No abstract available.

PMID:
30375345
9.

IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling.

Oliva CR, Halloran B, Hjelmeland AB, Vazquez A, Bailey SM, Sarkaria JN, Griguer CE.

Cell Commun Signal. 2018 Sep 19;16(1):61. doi: 10.1186/s12964-018-0273-7.

10.

Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus.

Steinhart AH, Panaccione R, Targownik L, Bressler B, Khanna R, Marshall JK, Afif W, Bernstein CN, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C.

Inflamm Bowel Dis. 2019 Jan 1;25(1):1-13. doi: 10.1093/ibd/izy247.

PMID:
30099529
11.

Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation.

Beilman CL, Kirwin E, Ma C, McCabe C, Fedorak RN, Halloran B.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1515-1524.e4. doi: 10.1016/j.cgh.2018.07.032. Epub 2018 Jul 26.

PMID:
30056180
12.

Supraphysiological Levels of Oxygen Exposure During the Neonatal Period Impairs Signaling Pathways Required for Learning and Memory.

Ramani M, Kumar R, Halloran B, Lal CV, Ambalavanan N, McMahon LL.

Sci Rep. 2018 Jul 2;8(1):9914. doi: 10.1038/s41598-018-28220-4.

13.

Iloprost attenuates hyperoxia-mediated impairment of lung development in newborn mice.

Olave N, Lal CV, Halloran B, Bhandari V, Ambalavanan N.

Am J Physiol Lung Cell Mol Physiol. 2018 Oct 1;315(4):L535-L544. doi: 10.1152/ajplung.00125.2017. Epub 2018 Jun 28.

14.

Innovative Online Educational Portal Improves Disease-Specific Reproductive Knowledge Among Patients With Inflammatory Bowel Disease.

Wierstra K, Sutton R, Bal J, Ismond K, Dieleman L, Halloran B, Kroeker K, Fedorak R, Berga KA, Huang V.

Inflamm Bowel Dis. 2018 Nov 29;24(12):2483-2493. doi: 10.1093/ibd/izy161.

PMID:
29850827
15.

Exosomal microRNA predicts and protects against severe bronchopulmonary dysplasia in extremely premature infants.

Lal CV, Olave N, Travers C, Rezonzew G, Dolma K, Simpson A, Halloran B, Aghai Z, Das P, Sharma N, Xu X, Genschmer K, Russell D, Szul T, Yi N, Blalock JE, Gaggar A, Bhandari V, Ambalavanan N.

JCI Insight. 2018 Mar 8;3(5). pii: 93994. doi: 10.1172/jci.insight.93994.

16.

MicroRNA-145 Antagonism Reverses TGF-β Inhibition of F508del CFTR Correction in Airway Epithelia.

Lutful Kabir F, Ambalavanan N, Liu G, Li P, Solomon GM, Lal CV, Mazur M, Halloran B, Szul T, Gerthoffer WT, Rowe SM, Harris WT.

Am J Respir Crit Care Med. 2018 Mar 1;197(5):632-643. doi: 10.1164/rccm.201704-0732OC.

17.

Exposure of neonatal mice to bromine impairs their alveolar development and lung function.

Jilling T, Ren C, Yee A, Aggarwal S, Halloran B, Ambalavanan N, Matalon S.

Am J Physiol Lung Cell Mol Physiol. 2018 Jan 1;314(1):L137-L143. doi: 10.1152/ajplung.00315.2017. Epub 2017 Sep 14.

18.

Prophylactic Groin Wound Vacuum-assisted Therapy in Vascular Surgery Patients at Enhanced Risk for Postoperative Wound Infection.

Pesonen LO, Halloran BG, Aziz A.

Ann Vasc Surg. 2018 Jan;46:127-133. doi: 10.1016/j.avsg.2017.07.009. Epub 2017 Jul 21.

PMID:
28739464
19.

Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study.

Ma C, Lumb R, Walker EV, Foshaug RR, Dang TT, Verma S, Huang VW, Kroeker KI, Wong K, Dieleman LA, Fedorak RN, Halloran BP.

Inflamm Bowel Dis. 2017 Sep;23(9):1643-1649. doi: 10.1097/MIB.0000000000001173.

PMID:
28644184
20.

Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.

Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, Kroeker KI, Seow CH, Leung Y, Novak KL, Halloran BP, Huang VW, Wong K, Blustein PK, Ghosh S, Panaccione R.

Inflamm Bowel Dis. 2017 May;23(5):833-839. doi: 10.1097/MIB.0000000000001074.

PMID:
28328624
21.

Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.

Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, Kroeker KI, Seow CH, Leung Y, Novak KL, Halloran BP, Huang VW, Wong K, Blustein PK, Ghosh S, Panaccione R.

Aliment Pharmacol Ther. 2017 May;45(9):1232-1243. doi: 10.1111/apt.14016. Epub 2017 Mar 2.

22.

Within-Stool and Within-Day Sample Variability of Fecal Calprotectin in Patients With Inflammatory Bowel Disease: A Prospective Observational Study.

Du L, Foshaug R, Huang VW, Kroeker KI, Dieleman LA, Halloran BP, Wong K, Fedorak RN.

J Clin Gastroenterol. 2018 Mar;52(3):235-240. doi: 10.1097/MCG.0000000000000776.

PMID:
28009684
23.

Inverted Meckel's Diverticulum with Intussusception and Ulceration Diagnosed after Rectal Double-Balloon Enteroscopy.

Al-Shankiti S, Halloran B, D'Urbano D, Zepeda-Gómez S.

ACG Case Rep J. 2016 Dec 7;3(4):e171. doi: 10.14309/crj.2016.144. eCollection 2016 Aug. No abstract available.

24.

Biomarkers associated with bronchopulmonary dysplasia/mortality in premature infants.

Balena-Borneman J, Ambalavanan N, Tiwari HK, Griffin RL, Halloran B, Askenazi D.

Pediatr Res. 2017 Mar;81(3):519-525. doi: 10.1038/pr.2016.259. Epub 2016 Nov 28.

25.

Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis.

Beilman CL, Thanh NX, Ung V, Ma C, Wong K, Kroeker KI, Lee T, Wang H, Ohinmaa A, Jacobs P, Halloran BP, Fedorak RN.

Can J Gastroenterol Hepatol. 2016;2016:5315798. Epub 2016 Oct 3.

26.

The Airway Microbiome at Birth.

Lal CV, Travers C, Aghai ZH, Eipers P, Jilling T, Halloran B, Carlo WA, Keeley J, Rezonzew G, Kumar R, Morrow C, Bhandari V, Ambalavanan N.

Sci Rep. 2016 Aug 4;6:31023. doi: 10.1038/srep31023.

27.

Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.

Ma C, Beilman CL, Huang VW, Fedorak DK, Wong K, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN.

Can J Gastroenterol Hepatol. 2016;2016:2079582. doi: 10.1155/2016/2079582. Epub 2016 Jul 11.

28.

Acute Kidney Injury Urine Biomarkers in Very Low-Birth-Weight Infants.

Askenazi DJ, Koralkar R, Patil N, Halloran B, Ambalavanan N, Griffin R.

Clin J Am Soc Nephrol. 2016 Sep 7;11(9):1527-35. doi: 10.2215/CJN.13381215. Epub 2016 Jul 28.

29.

Dietary dried plum increases bone mass, suppresses proinflammatory cytokines and promotes attainment of peak bone mass in male mice.

Shahnazari M, Turner RT, Iwaniec UT, Wronski TJ, Li M, Ferruzzi MG, Nissenson RA, Halloran BP.

J Nutr Biochem. 2016 Aug;34:73-82. doi: 10.1016/j.jnutbio.2016.04.007. Epub 2016 May 10.

PMID:
27239754
30.

Dried plum diet protects from bone loss caused by ionizing radiation.

Schreurs AS, Shirazi-Fard Y, Shahnazari M, Alwood JS, Truong TA, Tahimic CG, Limoli CL, Turner ND, Halloran B, Globus RK.

Sci Rep. 2016 Feb 11;6:21343. doi: 10.1038/srep21343.

31.

Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study.

Ma C, Beilman CL, Huang VW, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN.

Inflamm Bowel Dis. 2016 Apr;22(4):870-9. doi: 10.1097/MIB.0000000000000679.

PMID:
26818419
32.

Regulation of alveolar septation by microRNA-489.

Olave N, Lal CV, Halloran B, Pandit K, Cuna AC, Faye-Petersen OM, Kelly DR, Nicola T, Benos PV, Kaminski N, Ambalavanan N.

Am J Physiol Lung Cell Mol Physiol. 2016 Mar 1;310(5):L476-87. doi: 10.1152/ajplung.00145.2015. Epub 2015 Dec 30.

33.

Recurrent Fevers After Infliximab Therapy for Ulcerative Colitis.

Ma C, Fedorak RN, Halloran BP.

Gastroenterology. 2016 Jan;150(1):e1-2. doi: 10.1053/j.gastro.2015.04.048. Epub 2015 Nov 25. No abstract available.

PMID:
26627333
34.

Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders.

Lam GY, Halloran BP, Peters AC, Fedorak RN.

World J Gastrointest Pathophysiol. 2015 Nov 15;6(4):181-92. doi: 10.4291/wjgp.v6.i4.181. Review.

35.

Patients with Active Luminal Crohn's Disease Have Evidence of Significant Functional and Clinical Pulmonary Involvement.

Peerani F, Choi M, Weinkauf J, Fedorak RN, Halloran B.

Inflamm Bowel Dis. 2015 Aug;21(8):1817-24. doi: 10.1097/MIB.0000000000000442.

PMID:
26086595
36.

Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study.

Ma C, Evaschesen CJ, Gracias G, Huang VW, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN.

Can J Gastroenterol Hepatol. 2015 Aug-Sep;29(6):309-14. Epub 2015 Jun 12.

37.

Impact of gestational age, sex, and postnatal age on urine biomarkers in premature neonates.

Saeidi B, Koralkar R, Griffin RL, Halloran B, Ambalavanan N, Askenazi DJ.

Pediatr Nephrol. 2015 Nov;30(11):2037-44. doi: 10.1007/s00467-015-3129-z. Epub 2015 May 23.

38.

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy.

Huang VW, Prosser C, Kroeker KI, Wang H, Shalapay C, Dhami N, Fedorak DK, Halloran B, Dieleman LA, Goodman KJ, Fedorak RN.

Inflamm Bowel Dis. 2015 Jun;21(6):1359-67. doi: 10.1097/MIB.0000000000000376.

39.

Metagenomic analysis of microbiome in colon tissue from subjects with inflammatory bowel diseases reveals interplay of viruses and bacteria.

Wang W, Jovel J, Halloran B, Wine E, Patterson J, Ford G, OʼKeefe S, Meng B, Song D, Zhang Y, Tian Z, Wasilenko ST, Rahbari M, Reza S, Mitchell T, Jordan T, Carpenter E, Madsen K, Fedorak R, Dielemann LA, Ka-Shu Wong G, Mason AL.

Inflamm Bowel Dis. 2015 Jun;21(6):1419-27. doi: 10.1097/MIB.0000000000000344.

40.

Effects of blockade of endogenous Gi signaling in Tie2-expressing cells on bone formation in a mouse model of heterotopic ossification.

Wang L, Carroll DO, Liu X, Roth T, Kim H, Halloran B, Nissenson RA.

J Orthop Res. 2015 Aug;33(8):1212-7. doi: 10.1002/jor.22876. Epub 2015 May 20.

41.

Genetic polymorphisms of heme-oxygenase 1 (HO-1) may impact on acute kidney injury, bronchopulmonary dysplasia, and mortality in premature infants.

Askenazi DJ, Halloran B, Patil N, Keeling S, Saeidi B, Koralkar R, Ambalavanan N.

Pediatr Res. 2015 Jun;77(6):793-8. doi: 10.1038/pr.2015.44. Epub 2015 Mar 9.

42.

A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels.

Huang V, Dhami N, Fedorak D, Prosser C, Shalapay C, Kroeker KI, Halloran BP, Dieleman LA, Fedorak RN.

Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):35-40.

43.

VEGF mRNA and protein concentrations in the developing human eye.

Ma IT, McConaghy S, Namachivayam K, Halloran BA, Kurundkar AR, MohanKumar K, Maheshwari A, Ohls RK.

Pediatr Res. 2015 Apr;77(4):500-5. doi: 10.1038/pr.2015.15. Epub 2015 Jan 14.

44.

Epithelial-mesenchymal co-culture model for studying alveolar morphogenesis.

Greer RM, Miller JD, Okoh VO, Halloran BA, Prince LS.

Organogenesis. 2014;10(4):340-9. doi: 10.4161/org.29198. Epub 2014 Oct 31.

45.

Novel mouse model of spinal cord injury-induced heterotopic ossification.

Kang H, Dang AB, Joshi SK, Halloran B, Nissenson R, Zhang X, Li J, Kim HT, Liu X.

J Rehabil Res Dev. 2014;51(7):1109-18. doi: 10.1682/JRRD.2014.01.0019.

46.

Molecular patterns in human ulcerative colitis and correlation with response to infliximab.

Halloran B, Chang J, Shih DQ, McGovern D, Famulski K, Evaschesen C, Fedorak RN, Thiesen A, Targan S, Halloran PF.

Inflamm Bowel Dis. 2014 Dec;20(12):2353-63. doi: 10.1097/MIB.0000000000000239.

47.

Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.

Ma C, Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN.

J Clin Gastroenterol. 2015 Sep;49(8):675-82. doi: 10.1097/MCG.0000000000000265.

PMID:
25389599
48.

Alterations in gene expression and DNA methylation during murine and human lung alveolar septation.

Cuna A, Halloran B, Faye-Petersen O, Kelly D, Crossman DK, Cui X, Pandit K, Kaminski N, Bhattacharya S, Ahmad A, Mariani TJ, Ambalavanan N.

Am J Respir Cell Mol Biol. 2015 Jul;53(1):60-73. doi: 10.1165/rcmb.2014-0160OC.

49.

Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease.

Ma C, Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN.

Aliment Pharmacol Ther. 2014 Nov;40(9):1044-55. doi: 10.1111/apt.12940. Epub 2014 Sep 3.

50.

Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.

Ma C, Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN.

J Crohns Colitis. 2014 Nov;8(11):1454-63. doi: 10.1016/j.crohns.2014.05.007. Epub 2014 Jun 16.

PMID:
24947334

Supplemental Content

Loading ...
Support Center